Resources
4 Results (showing 1 - 4)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 10/12/2020 (updated 3/29/2024)
Built on an award winning, evidence-based prevention approach proven to reduce substance use, aggression and violence, our suite of digital products includes e-learning programs, an online educational game, and ancillary tools designed to provide schools, teachers, and parents with high quality content that can be used in school, at home, or in hybrid learning environments.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 4/12/2021 (updated 4/5/2024)
The National Center on Substance Abuse and Child Welfare (NCSACW), a program of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Administration on Children, Youth and Families (ACYF), prepared this document to support policy makers, administrators, and service providers. The goal of the document is to foster collaborative responses across multiple systems to improve safety, permanency, and well-being outcomes for infants, recovery for their parents, and to meet the needs of families and caregivers.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.